 Home > Medical News > Latest Medical News > BMS withdraws Opdivo monotherapy for sorafenib treatment failure indication for hepatocellular carcinoma

BMS withdraws Opdivo monotherapy for sorafenib treatment failure indication for hepatocellular carcinoma

 Last Update: 2021-08-05
 Source: Internet
 Author: User

Tags

indigo pre approval

albuterol drug card

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Text | pick up shells

On July 23, Bristol-Myers Squibb (BMS) announced that it had voluntarily withdrawn Opdivo (nivolumab) as a single drug in the US market for hepatocellular carcinoma (HCC) that had previously been treated with sorafenib after consultation with the US FDA.

Opdivo received accelerated approval from the FDA for the first time in 2017 for this indication, and is the first immunotherapy drug approved for use in this population

BMS said that in the case of single drug withdrawal, Opdivo and Yervoy combination therapy is still approved for HCC patients who have progressed after sorafenib treatment or are intolerant to sorafenib

Liver cancer is the fourth leading cause of cancer deaths in the world, and hepatocellular carcinoma (HCC) is the most common type of liver cancer, and it is also the fastest rising cause of cancer-related deaths in the United States

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.